Description and Brand Names
US Brand Name
- Zydelig
Descriptions
Idelalisib is used in combination with rituximab to treat chronic lymphocytic leukemia (CLL). This medicine is also used to treat follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) in patients who have received at least two previous treatments. Idelalisib interferes with the growth of cancer cells, which are eventually destroyed by the body. It is an antineoplastic agent (cancer medicine).
This medicine is available only with your doctor's prescription.
This product is available in the following dosage forms:
Portions of this document last updated: Oct. 01, 2019
Copyright © 2019 IBM Watson Health. All rights reserved. Information is for End User's use only and may not be sold, redistributed or otherwise used for commercial purposes.